Guidelines (2008) for the prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom

被引：123

作者：

Gould, F. Kate ^{[1
]}

Brindle, Richard ^{[2
]}

Chadwick, Paul R. ^{[3
]}

Fraise, Adam P. ^{[4
]}

Hill, Simon ^{[5
]}

Nathwani, Dilip ^{[6
]}

Ridgway, Geoff L. ^{[7
]}

Spry, Michael J. ^{[1
]}

Warren, Rod E. ^{[8
]}

机构：

[1] Freeman Rd Hosp, Dept Microbiol, Newcastle Upon Tyne NE7 7DN, Tyne & Wear, England

[2] Queen Alexandra Hosp, Dept Microbiol, Portsmouth PO6 3LY, Hants, England

[3] Salford Royal Hosp, Dept Microbiol, Salford M6 8HD, Lancs, England

[4] City Hosp NHS Trust, Dept Med Microbiol, Birmingham B18 7QH, W Midlands, England

[5] Poole Hosp, Dept Microbiol, Poole BH15 2JB, Dorset, England

[6] Univ Dundee, Ninewells Hosp & Med Sch, Infect Unit, Dundee DD1 9SY, Scotland

[7] Dept Hlth, London SE1 8UG, England

[8] Royal Shrewsbury Hosp, Dept Microbiol, Shrewsbury SY3 8XQ, Salop, England

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2009年 / 63卷 / 05期

关键词：

update; evidence-based guidelines; meticillin; new antistaphylococcal agents; UK; CRITICALLY-ILL PATIENTS; RISK-FACTORS; REDUCED SUSCEPTIBILITY; ENTEROCOCCUS-FAECIUM; ANTIMICROBIAL USE; COMPLICATED SKIN; INHIBITORY CONCENTRATION; NOSOCOMIAL TRANSMISSION; ANTIBIOTIC-TREATMENT; ENTERAL VANCOMYCIN;

D O I：

10.1093/jac/dkp065

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

These evidence-based guidelines are an updated version of those published in 2006. They have been produced after a literature review of the treatment and prophylaxis of methicillin-resistant Staphylococcus aureus (MRSA). The guidelines aim to complement those recently published for the antibiotic treatment of common and emerging community-onset MRSA infections in the UK. The guidelines have reviewed and updated, where appropriate, previous recommendations, taking into account any changes in the UK epidemiology of MRSA, ongoing national surveillance data and the value of new antistaphylococcal agents licensed for use in UK practice. Emerging therapies that have not been licensed for UK use are not reviewed, but their future potential role has been mentioned where deemed appropriate. Recommendations are given for the treatment of common infections caused by MRSA, elimination of MRSA from carriage sites and prophylaxis of surgical site infection.

引用

页码：849 / 861

页数：13

共 132 条

[1] The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections [J].

Arbeit, RD ;

Maki, D ;

Tally, FP ;

Campanaro, E ;

Eisenstein, BI .

CLINICAL INFECTIOUS DISEASES, 2004, 38 (12) :1673-1681

[2] A new UK strain of epidemic methicillin-resistant Staphylococcus aureus (EMRSA-17) resistant to multiple antibiotics [J].

Aucken, HM ;

Ganner, M ;

Murchan, S ;

Cookson, BD ;

Johnson, AP .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 (02) :171-175

[3]

Ayliffe GAJ, 1998, J HOSP INFECT, V39, P253, DOI 10.1016/S0195-6701(98)90293-6

[4]

AYLIFFE GAJ, 1979, LANCET, V1, P538

[5] Genome and virulence determinants of high virulence community-acquired MRSA [J].

Baba, T ;

Takeuchi, F ;

Kuroda, M ;

Yuzawa, H ;

Aoki, K ;

Oguchi, A ;

Nagai, Y ;

Iwama, N ;

Asano, K ;

Naimi, T ;

Kuroda, H ;

Cui, L ;

Yamamoto, K ;

Hiramatsu, K .

LANCET, 2002, 359 (9320) :1819-1827

[6] Staphylococcus aureus bacteremia in older adults:: Predictors of 7-day mortality and infection with a methicillin-resistant strain [J].

Bader, Mazen S. .

INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2006, 27 (11) :1219-1225

[7] Linezolid in the treatment of Gram-positive prosthetic joint infections [J].

Bassetti, M ;

Vitale, F ;

Melica, G ;

Righi, E ;

Di Biagio, A ;

Molfetta, L ;

Pipino, F ;

Cruciani, M ;

Bassetti, D .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2005, 55 (03) :387-390

[8] The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans [J].

Bergeron, M ;

Montay, G .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :129-138

[9] Characterisation of methicillin-resistant Staphylococcus aureus with reduced susceptibility to teicoplanin in eastern France [J].

Bertrand, X ;

Hocquet, D ;

Thouverez, M ;

Plésiat, P ;

Talon, D .

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2003, 22 (08) :504-506

[10] Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus [J].

Blot, SI ;

Vandewoude, KH ;

Hoste, EA ;

Colardyn, FA .

ARCHIVES OF INTERNAL MEDICINE, 2002, 162 (19) :2229-2235

← 1 2 3 4 5 6 7 8 9 10 →